Afya Limited delivered a clean beat in the third quarter. EPS of $0.39 topped the $0.36 consensus by 8.3%, and revenue of $191.72 million beat expectations by 6.2%. In dollar terms, earnings grew 5.4% year over year and revenue grew 12.5%. In reais, the company's reporting currency, revenue rose 6.1% to R$985.2 million and basic EPS rose 10.0% to R$1.88, so the dollar figures are shaped heavily by currency translation. The more important development was margin. Adjusted EBITDA rose 8.7% to R$433.8 million, and the 44.0% margin was up 100 basis points. That was the first year-over-year margin expansion of 2026, after declines of roughly 200 basis points in the first quarter and 190 basis points in the first half. The central tension is that this margin turn came entirely from the core medical school franchise, while the two businesses meant to extend Afya's reach across a physician's career weakened further.

The Undergraduate segment carried the quarter. Revenue rose 7.6%, and gross margin improved as health science programs scaled and class density increased. Health science students grew 18% over nine months, up from 13% at the first half, and medical school occupancy remained full. Elsewhere, the picture was weaker:

• Continuing Education revenue fell 7.4% in the quarter, and B2B revenue fell 34.1% year to date.
• Medical Practice Solutions revenue declined 2.7%.
• Both segments are now essentially flat for the nine months, and they partially offset the Undergraduate margin gain.

Beneath the headline, earnings quality is solid but not spotless. EPS grew faster than net income, which rose 7.2%, because of share repurchases. Adjusted EBITDA also added back R$11.9 million in M&A advisory costs tied to the merger.

The call made the deceleration in the adjacent segments explicit. Continuing Education revenue growth has slid from 11% in the first quarter to 5% in the first half to 1% for nine months. That falls well short of the high-single-digit second-half growth management described on the prior call. Student growth in the segment slowed from 23% to 10%, residency-journey students fell 4%, and graduate-journey growth dropped from 13% to 2%. Management now targets only mid-single-digit growth in 2027 and has pushed the B2B recovery to 2028. In Medical Practice Solutions, active payers rose 2% and the decline in monthly active users narrowed to 4% from 8%. Still, the Whitebook clinical-decision product faces pressure from AI tools, and clinical-decision payers fell 2.6%. Even in the core business, growth is easing:

• Medical seat growth has slowed to about 5%.
• Medical ticket growth has eased from roughly 5% to about 4%.

There are real offsets. The 2027 tuition increase is set at 5.7%, above the roughly 4.6% applied in the 2026 cycle. Seventeen new seats lifted approved capacity to 3,785. Internal assessments suggest students scored about 18 points better on ENAMED, with official results due in December. The release notes, however, that reported seat counts do not reflect any potential reductions tied to ENAMED, so the December results are a genuine binary risk. Cash generation also improved:

• Nine-month cash conversion reached 99.5%, up from 87.8% at the first half.
• Net debt fell to R$1.2 billion, or 0.7 times EBITDA, even after R$459.3 million returned to shareholders.

The cash story has caveats. Third-quarter free cash flow to equity of R$205.6 million was about 30% below last year. Pillar Two taxes were paid in cash for the first time. FIES-related receivables are rising. Capex of R$215.7 million through September runs well short of the R$340-380 million guidance, which implies either a heavy fourth quarter or underspending. Full-year guidance was reaffirmed, not raised.

The Yduqs merger reshapes the investment case. Afya shareholders would own 69% of the combined company at an exchange ratio of 6.408347 Yduqs shares per Afya share. The combined company would be listed only on B3. U.S. holders who do not qualify as eligible shareholders would receive cash from a post-closing sale rather than shares. Afya's value is therefore increasingly tied to Yduqs' share price, Brazilian antitrust review, and a closing deadline that runs to March 2028, rather than to quarterly operating results alone.

The market has not been generous. Shares at $10.73 are down 19.9% since the open after the August report and sit 23.5% below the 200-day moving average. The stock reached $15.25 on October 20, then collapsed to a 52-week low of $9.66 ten days later, and has recovered only about 11% from that low. Investor sentiment remains negative at -0.27, essentially unchanged from -0.29 before the report. Most Earnings Whispers trend readings, including price and AVWAP, remain negative.

The bottom line is that Afya produced a credible beat built on a durable, pricing-driven medical school franchise and a long-awaited margin inflection. Continuing Education and Medical Practice Solutions are losing momentum faster than management signaled just one quarter ago, and the pending Yduqs merger now matters more to shareholders than any single quarter. Bulls can point to a stronger 2027 tuition increase and improving cash flow. Bears have legitimate ammunition in the stalled adjacent segments, the ENAMED uncertainty, and a stock that has shown little appetite for good news.